Electroacupuncture improves follicular development and metabolism and regulates the expression of adiponectin,AMPK and ACC in an obese rat model of polycystic ovary syndrome
Restricted accessResearch articleFirst published online June, 2023
Electroacupuncture improves follicular development and metabolism and regulates the expression of adiponectin,AMPK and ACC in an obese rat model of polycystic ovary syndrome
Polycystic ovary syndrome (PCOS) is a common endocrine disorder characterized by hyperandrogenism and follicular arrest. Electroacupuncture (EA) has been shown to be effective at improving hyperandrogenism and follicular arrest in PCOS; however, its mechanism of action remains to be deciphered.
Objective:
In this study, we investigated whether EA improved follicular development in an obese rat model of PCOS and regulated the expression of adiponectin, AMP-activated protein kinase (AMPK) and acetyl-CoA carboxylase (ACC).
Methods:
EA was administered at CV3, CV4 and ST40. Changes in body weight, paraovarian fat, estrus cycle, ovarian morphology, levels of related hormones, and glucose and lipid metabolism were evaluated. In addition, protein and mRNA expression of adiponectin, AMPK and ACC was measured.
Results:
The body weight and paraovarian fat of rats in the EA group were reduced, while estrus cyclicity and ovarian morphology improved. Levels of free fatty acids, triglycerides, total cholesterol and low-density lipoprotein cholesterol were significantly reduced in the EA group, as well as blood glucose levels. Furthermore, levels of testosterone and luteinizing hormone were reduced in the EA group, while estradiol levels were increased. Protein and mRNA expression of adiponectin, AMPKα1 and liver kinase B1 (LKB1) was found to be increased in the EA group, while protein and mRNA expression of ACC were significantly reduced.
Conclusion: Our findings suggest that EA improved follicular development and metabolism and regulated expression levels of adiponectin, AMPKα1, LKB1 and ACC in our obese rat model of PCOS.
BozdagGMumusogluSZenginD, et al. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod2016; 31(12): 2841–2855.
2.
LiznevaDSuturinaLWalkerW, et al. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril2016; 106(1): 6–15.
3.
MaoXKikaniCKRiojasRA, et al. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nat Cell Biol2006; 8(5): 516–523.
4.
AghaieFKhazaliHHedayatiM, et al. The effects of exercise on expression of CYP19 and StAR mRNA in steroid-induced polycystic ovaries of female rats. Int J Fertil Steril2018; 11(4): 298–303.
5.
UrbanekM. The genetics of the polycystic ovary syndrome. Nat Clin Pract Endocrinol Metab2007; 3: 103–111.
6.
LiouTHYangJHHsiehCH, et al. Clinical and biochemical presentations of polycystic ovary syndrome among obese and nonobese women. Fertil Steril2009; 92(6): 1960–1965.
7.
ZhuSZhangBJiangX, et al. Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Fertil Steril2019; 111(1): 168–177.
8.
LimSSDaviesMJNormanRJ, et al. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update2012; 18(6): 618–637.
9.
WildRARizzoMCliftonS, et al. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril2011; 95(3): 1073.e11–1079.e11.
10.
Manneras-HolmLBenrickAStener-VictorinE. Gene expression in subcutaneous adipose tissue differs in women with polycystic ovary syndrome and controls matched pair-wise for age, body weight, and body mass index. Adipocyte2014; 3(3): 190–196.
11.
CortónMBotella-CarreteroJIBenguríaA, et al. Differential gene expression profile in omental adipose tissue in women with polycystic ovary syndrome. J Clin Endocrinol Metab2007; 92(1): 328–337.
12.
ChazenbalkGChenYHHeneidiS, et al. Abnormal expression of genes involved in inflammation, lipid metabolism, and Wnt signaling in the adipose tissue of polycystic ovary syndrome. J Clin Endocrinol Metab2012; 97(5): E765–E770.
13.
NiuZLinNGuR, et al. Associations between insulin resistance, free fatty acids, and oocyte quality in polycystic ovary syndrome during in vitro fertilization. J Clin Endocrinol Metab2014; 99(11): E2269–E2276.
14.
BrassardMAinMelkYBaillargeonJP. Basic infertility including polycystic ovary syndrome. Med Clin North Am2008; 92(5): 1163–1192, xi.
15.
KayaCCengizSDSatiroğluH. Obesity and insulin resistance associated with lower plasma vitamin B12 in PCOS. Reprod Biomed Online2009; 19(5): 721–726.
16.
Manneras-HolmLLeonhardtHKullbergJ, et al. Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab2011; 96(2): E304–E311.
17.
ToscaLSolnaisPFerréP, et al. Metformin-induced stimulation of adenosine 5’ monophosphate-activated protein kinase (PRKA) impairs progesterone secretion in rat granulosa cells. Biol Reprod2006; 75(3): 342–351.
18.
TaoXCaiLChenL, et al. Effects of metformin and Exenatide on insulin resistance and AMPKα-SIRT1 molecular pathway in PCOS rats. J Ovarian Res2019; 12(1): 86.
19.
SmithBKSteinbergGR. AMP-activated protein kinase, fatty acid metabolism, and insulin sensitivity. Curr Opin Clin Nutr Metab Care2017; 20(4): 248–253.
20.
BertevelloPSTeixeira-GomesAPSeyerA, et al. Lipid identification and transcriptional analysis of controlling enzymes in bovine ovarian follicle. Int J Mol Sci2018; 19(10): 3261.
21.
AritaYKiharaSOuchiN, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. 1999. Biochem Biophys Res Commun2012; 425(3): 560–564.
22.
MoranLJMissoMLWildRA, et al. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update2010; 16(4): 347–363.
23.
HafezMMusaNElbehairyS, et al. Effect of metformin on clinical and biochemical hyperandrogenism in adolescent girls with type 1 diabetes. J Pediatr Endocrinol Metab2019; 32(5): 461–470.
24.
YuLLiaoYWuH, et al. Effects of electroacupuncture and Chinese kidney-nourishing medicine on polycystic ovary syndrome in obese patients. J Tradit Chin Med2013; 33(3): 287–293.
25.
ShenKShouYZhangK. Effects on polycystic ovary syndrome of abdominal obesity treated with the dialing needling method at the abdomen. Zhongguo Zhen Jiu2018; 38(12): 1273–1276.
26.
KafaliHIriadamMOzardaliI, et al. Letrozole-induced polycystic ovaries in the rat: a new model for cystic ovarian disease. Arch Med Res2004; 35(2): 103–108.
27.
SunJJinCWuH, et al. Effects of electro-acupuncture on ovarian P450arom, P450c17α and mRNA expression induced by letrozole in PCOS rats. PLoS One2013; 8(11): e79382.
28.
ShiYLiLZhouJ, et al. Efficacy of electroacupuncture in regulating the imbalance of AMH and FSH to improve follicle development and hyperandrogenism in PCOS rats. Biomed Pharmacother2019; 113: 108687.
29.
KartinahNTSianiparIRNafi’ah, et al. The effects of exercise regimens on Irisin levels in obese rats model: comparing high-intensity intermittent with continuous moderate-intensity training. Biomed Res Int2018; 2018: 4708287.
30.
WangMXYinQXuX. A rat model of polycystic ovary syndrome with insulin resistance induced by letrozole combined with high fat diet. Med Sci Monit2020; 26: e922136.
31.
XuXHKouLCWangHM, et al. Genetic polymorphisms of melatonin receptors 1A and 1B may result in disordered lipid metabolism in obese patients with polycystic ovary syndrome. Mol Med Rep2019; 19(3): 2220–2230.
32.
KhanSASattarMZAAbdullahNA, et al. Improvement in baroreflex control of renal sympathetic nerve activity in obese Sprague Dawley rats following immunosuppression. Acta Physiol2017; 221(4): 250–265.
33.
NjelekelaMANegishiHNaraY, et al. Obesity and lipid profiles in middle aged men and women in Tanzania. East Afr Med J2002; 79(2): 58–64.
34.
ManneråsLCajanderSHolmängA, et al. A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome. Endocrinology2007; 148(8): 3781–3791.
35.
JohanssonJRedmanLVeldhuisPP, et al. Acupuncture for ovulation induction in polycystic ovary syndrome: a randomized controlled trial. Am J Physiol Endocrinol Metab2013; 304(9): E934–E943.
36.
LuSFTangYXZhangT, et al. Electroacupuncture reduces body weight by regulating fat browning-related proteins of adipose tissue in HFD-induced obese mice. Front Psychiatry2019; 10: 353.
37.
ShengJJinXZhuJ, et al. The effectiveness of acupoint catgut embedding therapy for abdominal obesity: a systematic review and meta-analysis. Evid Based Complement Alternat Med2019; 2019: 9714313.
38.
BaldaniDPSkrgaticLOugouagR, et al. The cardiometabolic effect of current management of polycystic ovary syndrome: strategies of prevention and treatment. Gynecol Endocrinol2018; 34(2): 87–91.
39.
JohanssonJStener-VictorinE. Polycystic ovary syndrome: effect and mechanisms of acupuncture for ovulation induction. Evid Based Complement Alternat Med2013; 2013: 762615.
40.
YeomMParkJLeeB, et al. Electroacupuncture ameliorates poloxamer 407-induced hyperlipidemia through suppressing hepatic SREBP-2 expression in rats. Life Sci2018; 203: 20–26.
41.
BarberTMMcCarthyMIWassJA, et al. Obesity and polycystic ovary syndrome. Clin Endocrinol2006; 65(2): 137–145.
42.
Olszanecka-GlinianowiczMKuglinDDabkowska-HucA, et al. Serum adiponectin and resistin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol2011; 154(1): 51–56.
43.
YamauchiTKamonJMinokoshiY, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med2002; 8(11): 1288–1295.
44.
HongSPLeiperFCWoodsA, et al. Activation of yeast Snf1 and mammalian AMP-activated protein kinase by upstream kinases. Proc Natl Acad Sci U S A2003; 100(15): 8839–8843.
45.
WoodsAJohnstoneSRDickersonK, et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol2003; 13(22): 2004–2008.
46.
AchariAEJainSK. Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. Int J Mol Sci2017; 18(6): 1321.
47.
ChowLSMashekDGWangQ, et al. Effect of acute physiological free fatty acid elevation in the context of hyperinsulinemia on fiber type-specific IMCL accumulation. J Appl Physiol2017; 123(1): 71–78.
48.
SunZChangHMWangA, et al. Identification of potential metabolic biomarkers of polycystic ovary syndrome in follicular fluid by SWATH mass spectrometry. Reprod Biol Endocrinol2019; 17(1): 45.
49.
BakaSMalamitsi-PuchnerA. Novel follicular fluid factors influencing oocyte developmental potential in IVF: a review. Reprod Biomed Online2006; 12(4): 500–506.
50.
MareiWFWathesDCFouladi-NashtaAA. Impact of linoleic acid on bovine oocyte maturation and embryo development. Reproduction2010; 139(6): 979–988.
51.
BelaniMDeoAShahP, et al. Differential insulin and steroidogenic signaling in insulin resistant and non-insulin resistant human luteinized granulosa cells—a study in PCOS patients. J Steroid Biochem Mol Biol2018; 178: 283–292.
52.
NormanRJDewaillyDLegroRS, et al. Polycystic ovary syndrome. Lancet2007; 370(9588): 685–697.
53.
MudaliSDobsASDingJ, et al. Endogenous postmenopausal hormones and serum lipids: the atherosclerosis risk in communities study. J Clin Endocrinol Metab2005; 90(2): 1202–1209.
54.
ZhangBWangJShenS, et al. Association of androgen excess with glucose intolerance in women with polycystic ovary syndrome. Biomed Res Int2018; 2018: 6869705.
MoranLJKoHMissoM, et al. Dietary composition in the treatment of polycystic ovary syndrome: a systematic review to inform evidence-based guidelines. Hum Reprod Update2013; 19(5): 432.
